Real time monitoring of opioid prescriptions: DORA and her big brother ERRCD
These are the slides that accompanied Raimondo Bruno's presentation to the 2013 National Drug Trends Conference.
These are the slides that accompanied Raimondo Bruno's presentation to the 2013 National Drug Trends Conference.
These are the powerpoint slides that accompanied Ms Joanne Gerstner-Stevens' presentation at the 2013 Drug Trends conference.
This presentation was delivered at the 2012 National Drug Trends Conference, themed 'Drugs, crime and the front line: Australasian perspective'.
This research project seeks to examine the patterns and costs of Pharmaceutical Benefits Scheme-subsidised opioid use, including extra-medical use, in the Australian population.
Opioid agonist treatment is commonly initiated as a first-line treatment for individuals with pharmaceutical opioid dependence, even though much of the evidence base for the use of pharmacotherapy treatments in opioid dependence has been derived from studies conducted with primarily or exclusivel
There has been very little evaluation of the effectiveness of strategies to assist GPs to manage chronic pain patients on prescription opioids, even high-risk patients.
There has been a recent increase in the prescribing of pharmaceutical opioids to Chronic Non-Cancer Pain (CNCP) patients in Australia which has led to increasing professional and public concern about the use and harms that may be related to such use.